Larimar Therapeutics IncNASDAQ:LRMR
- LAST PRICE5.3200
- TODAY'S CHANGE (%)0.3200 (6.4000%)
- Bid / Lots5.2600/ 3
- Ask / Lots5.3200/ 2
- Open / Previous Close4.8245 / 5.0000
- Day Range
- 52 Week Range
- Volume32,787
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LRMR |
|---|---|---|
| 09:32 ET | 1650 | 4.894 |
| 09:37 ET | 3447 | 4.96 |
| 09:48 ET | 100 | 4.95 |
| 10:02 ET | 200 | 4.9435 |
| 10:13 ET | 500 | 4.9599 |
| 10:20 ET | 2732 | 5.07 |
| 10:40 ET | 1000 | 5.15 |
| 10:51 ET | 3576 | 5.18 |
| 10:58 ET | 700 | 5.175 |
| 11:02 ET | 400 | 5.19 |
| 11:03 ET | 100 | 5.21 |
| 11:12 ET | 1800 | 5.22 |
| 11:20 ET | 100 | 5.25 |
| 11:21 ET | 600 | 5.2499 |
| 11:23 ET | 13553 | 5.3 |
| 11:25 ET | 100 | 5.32 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Larimar Therapeutics Inc | 216.3M | -2.9x | --- |
Tenaya Therapeutics Inc | 207.3M | -1.1x | --- |
Praxis Precision Medicines Inc | 225.7M | -0.9x | --- |
Cytodyn Inc | 225.9M | -1.0x | --- |
AC Immune SA | 207.2M | -2.6x | --- |
Singular Genomics Systems Inc | 204.2M | -2.3x | --- |
Company Information
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that are ineffective or have no treatments available. Its cell penetrating peptide (CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in a Phase I clinical program.
Contact Information
- Headquarters
- THREE BALA PLAZA EAST. SUITE 506BALA CYNWYD, PA, United States 19004
- Phone
- 617-622-4003
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Truitt
- President, Chief Executive Officer, Director
- Carole Ben-Maimon
- Chief Financial Officer, Company Secretary
- Michael Celano
- Independent Director
- Peter Barrett
- Independent Director
- Thomas Hamilton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $216.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 43.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.55 |
EPS | $-1.83 |
Book Value | $3.64 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
